Teva: The Market Is Pricing The Past, Not The Pipeline - Initiating Buy [Seeking Alpha]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Seeking Alpha
TEVA's key growth drivers include Austedo, Ajovy, Uzedy, and especially the late-stage immunology asset Duvakitug, which has shown compelling phase 2b efficacy and durability. Phase 2b data for Duvakitug in ulcerative colitis and Crohn's disease demonstrate robust remission rates and favorable safety, with multiple phase 3 trials underway. I initiate TEVA with a buy rating, citing visible earnings growth, pipeline optionality, and a favorable risk-reward despite ongoing legal and regulatory risks. Thomas Barwick/DigitalVision via Getty Images Introduction Teva Pharmaceuticals ( TEVA ) is a global pharmaceutical company historically known as the largest generics manufacturer, built through acquisitions, including the $40B Actavis Generics deal back in 2016. This strategy, in turn, resulted in I do not provide personal investment advice. All content in this article, including but not limited to opinions, analyses, commentaries, forecasts, stock picks, and investment strateg
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- How Teva Pharmaceutical Industries (TEVA) Story Is Shifting With Duvakitug R&D And Biosimilars [Yahoo! Finance]Yahoo! Finance
- Teva Launches Home Groundâ„¢ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care PartnersGlobeNewswire
- Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable ClinicsGlobeNewswire
- Teva Pharmaceutical Industries (TEVA) had its price target raised by Bank of America Corporation from $38.00 to $42.00. They now have a "buy" rating on the stock.MarketBeat
- Teva Pharmaceutical Industries Limited (TEVA): Billionaire Stan Druckenmiller Trims Position [Yahoo! Finance]Yahoo! Finance
TEVA
Earnings
- 1/28/26 - Beat
TEVA
Sec Filings
- 3/31/26 - Form DEFA14A
- 3/31/26 - Form ARS
- 3/31/26 - Form DEF
- TEVA's page on the SEC website